Details

Autor(en) / Beteiligte

• Li, C H
• Wei, S N
• Qiu, S W
• Gong, B F
• Gong, X Y
• Li, Y
• Liu, Y T
• Fang, Q Y
• Zhang, G J
• Liu, K Q
• Zhou, C L
• Lin, D
• Liu, B C
• Wang, Y
• Mi, Y C
• Wei, H
• Wang, J X

Titel

Efficacy and safety of IAC regimen for relapse/refractory acute myeloid leukemia: a prospective randomized controlled study

Ist Teil von

• Zhōnghuá xuèyèxué zázhì, 2022-04, Vol.43 (4), p.287

Ort / Verlag

China

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• To evaluate the efficacy and toxicity profiles of idarubicin, cytarabine, and cyclophosphamide (IAC) in relapse/refractory acute myeloid leukemia (AML) . This study was a prospective, randomized controlled clinical trial with the registration number NCT02937662. The patients were randomly divided into two groups. The experimental group was treated with an IAC regimen, and the regimen of the control group was selected by doctors according to medication experience. After salvage chemotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was conducted as far as possible according to the situation of the patients. We aimed to observe the efficacy, safety, and toxicity of the IAC regimen in relapse/refractory AML and to explore which is the better regimen. Forty-two patients were enrolled in the clinical trial, with a median age of 36 years (IAC group, 22 cases and control groups, 20 cases) . ①The objective response rate was 71.4% in the IAC group and 40.0% in the control group ( =0.062) ; the co